https://www.israelnationalnews.com/News/News.aspx/313613
A serological study carried out at Sheba Medical Center in Ramat Gan has found that the antibodies levels in people who have received the third dose of the Pfizer coronavirus vaccine are ten times higher than in people who received the second dose.
The study was conducted by the Weizmann Institute of Science, the Ministry of Health, the Technion, the Hebrew University, the Gartner Institute at Sheba Medical Center and the KI Institute, and measured antibody levels a week after the administration of the vaccine.
The findings were published today (Thursday) in The New England Journal of Medicine.
According to the study, the third dose restores the vaccines effectiveness against the coronavirus to 95% after the level of protection drops in the months following the administration of the second vaccine dose.
10x on log scale isn't much higher.
ReplyDeleteThe "effectiveness" the NEJM study is referring to is only in a study of age 60 and older.